Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

CHEMICAL SYNOVIORTHESIS WITH EMICINE



Abstract

This is a non controlled experimental prospective4 clinical study that obtained satisfactory results in the chemical Synovectomy with Oxitetracycline Clorhydrate (Emicine), in dfferent joints, demonstrating that it is an Effective method in the treatment of recurrent haemarthrosis in haemophilia.

Materials: 84 patients of whom 77 concluded the complete treatment. 82 joints were injected. The dosage injected was 5 cc of the drug (25 mgms.) in 5 cc of anaesthesia for the knee. 2 cc with 1 cc anaesthesia for the elbow. 1 cc plus 1 cc anaesthesia for the ankle. These injections were performed once weekly with a reinforcement in one month. In case of failure the same can be done repeatedly.

Evaluation and results: Subjective parameters. Pain, range of movement and use of the joint involved. Pain decreased from a mean of 6.5 to 0.9 (Likert scale). Range of movement increased from 5.9 to 9 and joint use increased from 5.9 to 9.2. Objective parameters. Joint diameter and range of movement. Range of movement for flexion and extensiòn improved from 72.2 and 149.2 to 73.7 and 167 respectively for the knees. From 57.3 and 160 to 66.6 and 170 respectively for the shoulder. And from 22.7 and 10.8 to 34 and 18.6 respectively for the ankle.

Conclusion: This procedure has multiple advantages such as immediate therapeutic effect, short period of treatment, easy technique, much les AHF coverage (•0% above coagulation level, less cost than radiocolloid treatment which makes it an perfect alternative of treatment for developing countries and not so underdeveloped.

Besides the experimental demonstration of its action in rabbits is exposed.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org